Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage
Condition(s) studied
Investigational drug(s) / intervention(s)
Carbetocin: Carbetocin will be administered as a single intravenous dose immediately following delivery of the second twin, according to institutional protocol, for the prevention of postpartum hemorrhage.
Oxytocin: Oxytocin will be administered intravenously according to standard institutional practice, for the prevention of postpartum hemorrhage.
Study summary
The goal of this clinical trial is to learn if the drug carbetocin works better than standard care to prevent heavy bleeding after childbirth in people carrying twin pregnancies. Heavy bleeding after delivery, also called postpartum hemorrhage, is more common after twin births and can lead to anemia, blood transfusions, and other serious health problems.
In this study, bleeding will be evaluated by measuring how much blood hemoglobin levels drop from before delivery to the day after delivery.
The main questions this study aims to answer are:
* Does giving carbetocin after delivery lower blood loss compared with standard oxytocin treatment?
* Is carbetocin safe and practical to use in twin deliveries?
Researchers will compare carbetocin to standard oxytocin treatment to see which approach better prevents bleeding after twin vaginal or cesarean delivery.
Participants will:
* Be randomly assigned to receive either carbetocin or standard oxytocin after the second twin is delivered
* Have blood tests before delivery and on the day after delivery
* Be followed during their hospital stay and for up to six weeks after delivery for safety outcomes
Eligibility
Primary outcome measure(s)
- Change in maternal hemoglobin level from baseline to postpartum — The most recent hemoglobin measurement taken within 30 days prior to delivery to the day after delivery.
The primary outcome is the change in maternal hemoglobin level, defined as the difference between pre-delivery hemoglobin and hemoglobin measured on the day after delivery.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Sheba Medical Center | Ramat Gan | Israel | Recruiting |
More Sheba Medical Center trials in Israel
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07401524 on ClinicalTrials.gov ↗ ← All trials in Israel